{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:34:32Z","timestamp":1772692472626,"version":"3.50.1"},"reference-count":61,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"655","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2022,7,27]]},"abstract":"<jats:p>As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of 6 months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech\/Pfizer) COVID-19 mRNA vaccines. This post hoc analysis assessed the immune response to vaccination for 135 participants without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not efficiently bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo recipients mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk category, and vaccine type with any observed differences of uncertain clinical importance. These findings are pertinent for informing public health policy with results that suggest that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 monoclonal antibody infusion.<\/jats:p>","DOI":"10.1126\/scitranslmed.abn3041","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T13:58:14Z","timestamp":1654783094000},"source":"Crossref","is-referenced-by-count":32,"title":["The anti\u2013SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination"],"prefix":"10.1126","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6313-5218","authenticated-orcid":true,"given":"Robert J.","family":"Benschop","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-2075","authenticated-orcid":true,"given":"Jay L.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Poorbaugh","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole L.","family":"Kallewaard","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vaillancourt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8074-0268","authenticated-orcid":true,"given":"Melissa","family":"Crisp","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-7260","authenticated-orcid":true,"given":"Thi Ngoc Vy","family":"Trinh","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2752-3413","authenticated-orcid":true,"given":"Joshua J.","family":"Freitas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Beasley","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-0531","authenticated-orcid":true,"given":"Montanea","family":"Daniels","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-188X","authenticated-orcid":true,"given":"Natalie","family":"Haustrup","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0162-4109","authenticated-orcid":true,"given":"Richard E.","family":"Higgs","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN 46225, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-9664","authenticated-orcid":true,"given":"Myron S.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-3748","authenticated-orcid":true,"given":"Mary","family":"Marovich","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20850, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00588-2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30354-4"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0202"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"M. K. Slifka I. J. Amanna in Plotkin\u2019s Vaccines (Seventh Edition) S. A. Plotkin W. A. Orenstein P. A. Offit K. M. Edwards Eds. (Elsevier 2018) pp. 84\u201395.e10.","DOI":"10.1016\/B978-0-323-35761-6.00008-0"},{"key":"e_1_3_3_10_2","unstructured":"U.S. Food and Drug Administration Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab and etesevimab (2021); www.fda.gov\/media\/145802\/download."},{"key":"e_1_3_3_11_2","unstructured":"U.S. Food and Drug Administration Fact sheet for health care providers: Emergency Use Authorization (EUA) of caririvimab and imdevimab (2021); www.regeneron.com\/downloads\/treatment-covid19-eua-fact-sheet-for-hcp.pdf."},{"key":"e_1_3_3_12_2","unstructured":"U.S. Food and Drug Administration Fact sheet for health care providers: Emergency Use Authorization (EUA) of bamlanivimab (2020); www.fda.gov\/media\/143603\/download."},{"key":"e_1_3_3_13_2","unstructured":"U.S. Food and Drug Administration Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19 (2021)."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.77299"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.178061"},{"key":"e_1_3_3_17_2","unstructured":"Centers for Disease Control and Prevention Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States (2021; accessed 9 November 2021)."},{"key":"e_1_3_3_18_2","unstructured":"World Health Organization Interim recommendations for use of the Pfizer\u2013BioNTech COVID-19 vaccine BNT162b2 under Emergency Use Listing (2021)."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm3425"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj0299"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1227"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab420"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8828"},{"key":"e_1_3_3_24_2","unstructured":"Centers for Disease Control and Prevention When you\u2019ve been fully vaccinated. (2021); www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/fully-vaccinated.html."},{"key":"e_1_3_3_25_2","unstructured":"Fact sheet for healthcare providers administering vaccine - Emergency Use Authorization of the Pfizer-BioNTech vaccine to prevent coronavirus disease 2019 (COVID-19) (2021)."},{"key":"e_1_3_3_26_2","unstructured":"Fact sheet for healthcare providers administering vaccine (vaccination providers) - Emergency Use Authorization of the Moderna COVID-19 vaccine to prevent coronavirus 2019 (COVID-19) (2021)."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1906"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2381-y"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100255"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.036"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2405"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03944-y"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03412-7"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15125"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00220-4"},{"key":"e_1_3_3_39_2","unstructured":"People with certain medical conditions. Certain medical condititions and risk for severe COVID-19 illness (November 2 2020; accessed September 23 2021)."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0321-6"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00542-x"},{"key":"e_1_3_3_42_2","first-page":"2065","article-title":"Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination","volume":"73","author":"M\u00fcller L.","year":"2021","unstructured":"L. M\u00fcller, M. Andr\u00e9e, W. Moskorz, I. Drexler, L. Walotka, R. Grothmann, J. Ptok, J. Hillebrandt, A. Ritchie, D. Rabl, P. N. Ostermann, R. Robitzsch, S. Hauka, A. Walker, C. Menne, R. Grutza, J. Timm, O. Adams, H. Schaal, Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination. Clin. Infect. Dis. 73, 2065\u20132072 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_43_2","unstructured":"Pfizer and BioNTech Pfizer and BioNTech provide update on Omicron variant. (2021); www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-provide-update-omicron-variant."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.033"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1903879"},{"key":"e_1_3_3_46_2","unstructured":"R. Walensky CDC expands COVID-19 booster recommendations (2021); www.cdc.gov\/media\/releases\/2021\/s1129-booster-recommendations.html."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19499"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00880-9"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119407"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2420"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790469"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.11.010"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01649-6"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9599-2"},{"key":"e_1_3_3_60_2","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing 2017)."},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087057105285611"},{"key":"e_1_3_3_62_2","unstructured":"J. V. Haas B. J. Eastwood P. W. Iversen V. Devanarayan J. R. Weidner Minimum significant ratio\u2014A statistic to assess assay variability in Assay Guidance Manual S. Markossian K. Brimacombe Eds. (National Institutes of Health - National Center for Advancing Translational Sciences 2017); www.ncbi.nlm.nih.gov\/books\/NBK169432\/."}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.abn3041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T13:27:43Z","timestamp":1705411663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.abn3041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":61,"journal-issue":{"issue":"655","published-print":{"date-parts":[[2022,7,27]]}},"alternative-id":["10.1126\/scitranslmed.abn3041"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.abn3041","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.15.21267605","asserted-by":"object"}]},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"article-number":"eabn3041"}}